<DOC>
	<DOC>NCT00393523</DOC>
	<brief_summary>To assess the safety and immunogenicity of a booster dose of hepatitis B vaccine in children who have received a 3-dose primary series of either RECOMBIVAX HB or ENGERIX-B. The primary vaccination series (was given 4 to 8 years prior to study entry and consisted of a licensed hepatitis B vaccine product (either RECOMBIVAX HB or ENGERIX-B). The booster dose given in this study will be either an investigational Merck product (Modified Process Hepatitis B Vaccine) or licensed ENGERIX-B vaccine.</brief_summary>
	<brief_title>Hepatitis B Vaccine Booster Study (V232-058)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Children 4 to 8 years of age Complete medical records documenting receiving a previous hepatitis B vaccination during the first year of life (for Cohort A and B only) Complete 3dose vaccination with either a primary series of RECOMBIVAX HB or a primary series of ENGERIXB (for Cohort A and B only) Birth mother known to be a carrier of hepatitis B virus (Cohort C only) History of previous hepatitis B vaccine History of vaccination with any hepatitis B vaccine (Cohort C only) Known of suspected hypersensitivity to any component of RECOMBIVAX HB or ENGERIXB (eg aluminum, yeast) recent administration of hepatitis B immune globulin (HBIg), serum immune globulin, or any other bloodderived product Receipt of investigational drugs or vaccines within 3 months prior to study vaccine or planned within study period Impairment of immunologic function or recent use of immunomodulatory medications A Combination of different hepatitis B vaccines used in the primary vaccination series (Cohort A and B only)</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>